THERE is growing interest in the individuality of human tumours with respect to cytotoxic drug sensitivity. That human tumours differ in response to chemotherapy is well known; some diseases, including choriocarcinoma and non-seminomatous tumours of the testis, usually respond well, in contrast, for example, to adenocarcinomas and squamous carcinomas in various sites, that respond poorly if at all. The question is, within a well-defined category of tumour, how wide is the range of drug sensitivity and is there firm evidence that the best drug to use may differ from one tumour to the next? In other words, among what is thought to be a group of otherwise identical tumours are there differences in the spectrum of drug response? There is widespread belief that such differences do exist. The current wave of interest in techniques by which the chemosensitivity of individual tumours can be evaluated (Salmon et al., 1978; Hamburger, 1981) arises from the belief that individualizing chemotherapy can achieve useful improvements in treatment. Studies on a group of mouse colon tumours have also given evidence for their chemotherapeutic individuality (Double et al., 1975) .
Our programme of work on the chemotherapeutic response of human tumours grown as xenografts in immune-deprived mice has given some evidence in support of the individuality hypothesis. Nowak et al. (1978) Houghton & Houghton (1978) came to a similar conclusion, also on colo-rectal cancer. In a study of breast-cancer xenografts, Bailey et al. (1980) examined the response of 5 tumour lines to 6 single agents and 2 drug combinations. Melphalan alone, and the 2 combinations, were on average the best treatments, but among these the ranking varied from one tumour line to the next. Bateman et al. (1980) used in vitro drug sensitivity tests to rank the response of 5 malignant melanoma xenografts to each of 8 chemotherapeutic agents. Here again there was a similar picture, with an overall trend in drug ranking (in this case favouring melphalan, MeCCNU and cis-platin) superimposed on which was some evidence for individuality. In none of these studies was the evidence for individuality statistically significant, but it encouraged further attempts to confirm this phenomenon.
The present work comprised a detailed study on two pancreatic carcinoma xenograft lines. The first, which we have called HX32, was established by Pickard (1975) . It was used in the radiobiological study described by Courtenay et al. (1976) and is described in more detail by Courte-nay & Mills (1978) . The second xenograft line (designated HX58) originated from a peritoneal metastasis of an adenocarcinoma of the head of the pancreas in a 51-year-old man. The 2 tumours have a similar histological appearance, consistent with derivation from the exocrine pancreas. The object of the study was to determine the sensitivity of these 2 tumours to 6 chemotherapeutic agents. Clonogenic cell-survival curves were determined following in vivo drug administration, in order to obtain precise estimates of cellular sensitivity.
The tumours were maintained by repeated passage in immune-suppressed CBA mice. Following thymectomy at 4 weeks of age, mice were allowed to recover for at least 2 weeks before being given a whole-body dose of 9 Gy 60Co y-radiation. Radiation death was prevented by pretreating with 200 mg/kg cytosine arabinoside i.p. 2 days before irradiation. The latter technique obviates the need for a marrow graft and slightly improves receptivity to subsequent grafting .
The present therapeutic studies were performed on i.m. hind-leg tumours, produced by injecting a suspension of 5 xenograft line to melphalan which achieved 3 decades of cell kill in each tumour line at the MTD. The remarkable feature of these data is the evidence for identical sensitivity to 4 of the drugs, but for a marked difference in sensitivity to hexamethylmelamine. The data for cis-platin, melphalan, MeCCNU, and streptozotocin are indistinguishable between the 2 tumour lines. Hexamethylmelamine, in contrast, produced ov-er 2 decades of cell kill in HX32 and barely detectable cell kill in HX58. Cyclophosphamide was not very effective in either of the tumours, but there was evidence for systematically greater effects in HX58.
In our view this is one of the clearest demonstrations so far reported of signficant differences in spectrum of drug sensitivity between 2 very similar xenograft lines of human cancer. The similarity in sensitivity to the 4 drugs is remarkable, as is the magnitude of the difference in sensitivity to HMM. It would seem that a small unidentified difference must exist between the 2 tumours in the way they incorporate or respond to HMM.
Further work is required before it will be possible to assess the potential benefits of individualized cancer chemotherapy. The view has strongly been expressed by Salmon et al. (1980) that studies using their direct soft-agar cloning assay have demonstrated individuality in drug sensitivity. We are not convinced by these claims, partly because of technical inadequacies in the assay (Lancet, 1982) and because it is impossible with only a single specimen from each patient to distinguish scatter in the data due to technical factors from scatter that truly reflects differences in chemosensitivity. In contrast, each curve in the Figure  combines the results of 3-4 repeat experiments on different passages of each tumour line, and we therefore have some confidence in claiming that the tumour lines are similar in response to some drugs and different in response to hexamethylmelamine.
It may well be that the results obtained here illustrate 3 principles that could apply more widely: the overall tendency for some drugs to be generally much more effective than others; a tendency for tumours of the same type to show strong similarity in response to most of the agents available; and an element of individuality which at times could become therapeutically important.
